A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia

Nintedanib (BIBF 1120), a potent multikinase inhibitor of VEGFR-1/-2/-3, FGFR-1/-2/-3 and PDGFR-α/-β, exerts growth inhibitory and pro-apoptotic effects in myeloid leukemic cells, especially when used in combination with cytarabine. This phase I study evaluated nintedanib in combination with low-dos...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2016-10, Vol.11 (10), p.e0164499
Hauptverfasser:	Schliemann, Christoph, Gerss, Joachim, Wiebe, Stefanie, Mikesch, Jan-Henrik, Knoblauch, Nicola, Sauer, Tim, Angenendt, Linus, Kewitz, Tobias, Urban, Marc, Butterfass-Bahloul, Trude, Edemir, Sabine, Vehring, Kerstin, Müller-Tidow, Carsten, Berdel, Wolfgang E, Krug, Utz
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myelocytic leukemia Acute myeloid leukemia Aged Aged, 80 and over Angiogenesis Antimetabolites, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - adverse effects Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Apoptosis Biology and Life Sciences Blood pressure Bone marrow Cancer therapies Chemotherapy Clinical trials Cytarabine Cytarabine - administration & dosage Cytarabine - adverse effects Cytogenetics Disease Dosage and administration Drug dosages Drugs Elderly patients Enzyme Inhibitors - administration & dosage Enzyme Inhibitors - adverse effects Female Fibroblast growth factor receptors Gastrointestinal diseases Geriatrics Health aspects Hematology Hepatitis Hospitals Humans Hypercalcemia Indoles - administration & dosage Indoles - adverse effects Inhibitors Leukemia Leukemia, Myeloid, Acute - drug therapy Male Medical prognosis Medical research Medicine Medicine and Health Sciences Middle Aged Myeloid leukemia Older people Patients People and Places Pneumoviridae Protein Kinase Inhibitors - adverse effects Quality Remission Slopes Survival Toxicity Tumors Vascular endothelial growth factor Vascular endothelial growth factor receptors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!